Harrow Q3 revenue up 22% to $22.8M; FDA approves IHEEZO, narrows net loss

HARROW, INC.

2023-Q3 EPS reported -$0.55 revenue$68,266,000

Revenue $22.8M (+22% YoY); net loss narrowed to $6.5M from $8.3M; adjusted EBITDA $2.5M vs. -$0.1M.
FDA approved IHEEZO (ocular anesthetic NDA) on Sept 27; launch expected to double revenues within 24 months.
Launched Fortisite (fortified antibiotics) and atropine.com; sold non-ophthalmic product line to become pure-play.
Core net loss per share ($0.06) improved from ($0.20); revenue per shipping day $355K (+21%).
Nearly $1M order backlog at quarter end due to supply chain issues; cleared in Q4; scaling production.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.97

HARROW, INC. reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 14, 2022, Harrow Health, Inc. (the “Company”) issued a press release and a letter to stockholders announcing its financial results for the period ended September 30, 2022 and an update on recent corporate events.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

HARROW, INC. filing history →

Source: SEC EDGAR

accession 0001493152-22-032070

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.